- Patent Title: Hesperetin and trans-resveratrol compositions and methods thereof
-
Application No.: US15775692Application Date: 2016-11-07
-
Publication No.: US11135145B2Publication Date: 2021-10-05
- Inventor: Mark Ian Fowler , Gail Jenkins , David James Messenger , Naila Rabbani , Paul John Thornalley , Mingzhan Xue
- Applicant: Paul John Thornalley , Naila Rabbani , Mingzhan Xue
- Applicant Address: GB Kenilworth; GB Kenilworth; GB Colchester
- Assignee: Paul John Thornalley,Naila Rabbani,Mingzhan Xue
- Current Assignee: Paul John Thornalley,Naila Rabbani,Mingzhan Xue
- Current Assignee Address: GB Kenilworth; GB Kenilworth; GB Colchester
- Agency: Christensen O'Connor Johnson Kindness PLLC
- Priority: EP15194461.8 20151113
- International Application: PCT/EP2016/076858 WO 20161107
- International Announcement: WO2017/080958 WO 20170518
- Main IPC: A61K31/35
- IPC: A61K31/35 ; A61K8/49 ; A61K8/34 ; A61Q7/00 ; A61P9/00 ; A61K31/05 ; A61K31/09 ; A61K31/353

Abstract:
The invention relates to a composition, in particular to an oral anti-ageing composition for treating hair ageing. This invention is based on the observation that the combination of hesperetin, a flavanone, derivable from a natural rutinoside hesperetin 7-rutinoside (also known as hesperidin) in citrus, e.g., in Citrus aurantium L, Citrus sinensis, Zanthozylum gilletti, leaves of Agathosma serratifolia, and trans-resveratrol synergistically up-regulates NQO-1 in a gene expression assay. The combination also induces Glo1, decreases MG and MG-protein glycation, decreases insulin resistance, decreases fasting plasma glucose, induces modest weight loss, improves renal function, decreases vascular inflammation marker slCAM-1, improves arterial dilatation and decreases the risk of cardiovascular disease. Thus is one aspect of the invention, a composition is provided, the composition comprising a combination of: (a) 30-10000, preferably 60-5000, most preferably 60-2500 mg in the form of an equivalent daily dose of flavanone of structure (I) wherein R is —H or —CH3, and mono-, di- and tri-acylated derivatives thereof; and (b) 20-1000, preferably 45-750, most preferably 45-500 mg in the form of an equivalent daily dose stilbenoid, wherein the composition comprises at least 0.5% w/w flavanone of structure I.
Public/Granted literature
- US20180344603A1 COMPOSITION FOR HAIR FOLLICLE GROWTH Public/Granted day:2018-12-06
Information query